FDA is taking steps that could provide some greater predictability for pharmaceutical companies importing drugs or drug ingredients into to the U.S, a new agency action plan indicates.
A risk-based imports entry review strategy for pharmaceutical products will be established and implemented during the first quarter of fiscal year 2015, which began Oct. 1.